Article Details

Neoadjuvant Nivolumab Plus Chemotherapy Bests Nivolumab Alone in Resectable NSCLC

Retrieved on: 2022-12-09 14:08:56

Tags for this article:

Click the tags to see associated articles and topics

Neoadjuvant Nivolumab Plus Chemotherapy Bests Nivolumab Alone in Resectable NSCLC. View article details on hiswai:

Excerpt

... Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences in Guangzhou, China, said in a presentation of the findings.

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up